A 28-year-old woman with HIV-1 infection (CD4 count 320 cells/μL, viral load 45,000 copies/mL) has been on a stable regimen of tenofovir/emtricitabine plus efavirenz for 18 months. Repeat CD4 count is now 580 cells/μL with undetectable viral load. She plans to conceive in 6 months and asks about her antiretroviral regimen. Baseline renal function (creatinine 0.8 mg/dL, eGFR 95 mL/min/1.73 m²) and bone density (T-score −1.2 at lumbar spine) are documented. Which change to her antiretroviral regimen is most appropriate?

Explanation

## Antiretroviral Management in Pregnancy The patient is virologically suppressed and immunologically recovered, but her current regimen has concerns for pregnancy planning: ### Efavirenz in Pregnancy **High-Yield:** Efavirenz is **contraindicated in pregnancy**, particularly in the first trimester, due to: - Animal teratogenicity data (CNS malformations in primates) - Case reports of neural tube defects in humans (though causality not definitively proven) - WHO and most guidelines recommend avoiding in women of childbearing potential - If conception occurs on efavirenz, continuation is not absolutely contraindicated if virologically suppressed, but switching is preferred ### Tenofovir (Tenofovir Disoproxil Fumarate, TDF) Concerns **Key Point:** While TDF is not absolutely contraindicated in pregnancy, it carries: - Chronic renal toxicity risk (this patient already has T-score −1.2, indicating bone loss) - Bone demineralization concerns in pregnancy and lactation - Tenofovir alafenamide (TAF) is preferred in pregnancy due to lower renal/bone toxicity ### Optimal Regimen for Pregnancy **Clinical Pearl:** The preferred regimen for women planning pregnancy is: - **Nucleoside backbone:** Abacavir/lamivudine (or TDF/emtricitabine if no renal/bone concerns) - **Third agent:** Integrase inhibitor (dolutegravir preferred) or protease inhibitor (lopinavir/ritonavir) - **Avoid:** Efavirenz, nevirapine (in women with CD4 >250), certain protease inhibitors **Mnemonic:** **PINT** — Preferred In pregNancy for Third agent = Protease inhibitors, Integrase inhibitors, (NOT NNRTIs) ### Why Abacavir + Integrase Inhibitor? 1. **Abacavir:** No teratogenic signal, good placental penetration, maintains virologic suppression 2. **Integrase inhibitor (e.g., dolutegravir):** Excellent safety profile in pregnancy, high barrier to resistance, minimal fetal toxicity 3. **Avoids efavirenz:** Removes CNS teratogenicity concern 4. **Avoids TDF:** Reduces bone demineralization risk (important given her T-score) ## Comparison Table: Antiretrovirals in Pregnancy | Agent Class | Agent | Pregnancy Safety | Comments | |-------------|-------|------------------|----------| | **NNRTI** | Efavirenz | **Avoid** | Teratogenicity concern, esp. 1st trimester | | **NNRTI** | Nevirapine | Caution | Hepatotoxicity risk if CD4 >250; not preferred | | **NRTI** | Abacavir | **Preferred** | No teratogenic signal, good outcomes | | **NRTI** | Tenofovir (TDF) | Acceptable | Bone/renal toxicity; TAF preferred | | **Integrase** | Dolutegravir | **Preferred** | Excellent safety, high efficacy | | **Integrase** | Bictegravir | **Preferred** | Newer, good safety data | | **PI** | Lopinavir/ritonavir | Acceptable | Older choice, still safe; GI side effects | **Warning:** Nevirapine is NOT preferred in pregnancy despite good placental penetration—hepatotoxicity risk in women with CD4 >250 (this patient has CD4 580) makes it unsuitable. ## Adherence & Virologic Suppression **Key Point:** Undetectable viral load (UVL) = Undetectable = Untransmittable (U=U). Maintaining UVL throughout pregnancy is the single most important factor for preventing mother-to-child transmission (MTCT). Regimen changes should prioritize: 1. Maintaining virologic suppression 2. Minimizing teratogenic/toxic agents 3. High adherence potential [cite:Harrison 21e Ch 197; WHO Guidelines on HIV in Pregnancy 2023]